💨 Abstract

ANI Pharmaceuticals reported $8.5 million net income for Q2 2025, a significant improvement from a loss in the same period the previous year. With earnings of $1.80 per share (adjusted) and revenue of $211.4 million, the company exceeded Wall Street expectations. ANI's full-year revenue is projected to be between $818 million and $843 million.

Courtesy: WTOP Staff